Leucine 7 to proline 7 polymorphism of the preproneuropeptide Y gene is not associated with restenosis after coronary stenting

Journal of Endovascular Therapy

Volumn 10, Issue 3, 2003, Pages 566-572

  Pesonen, Ullamari ^a   Koch, Werner ^b   Schömig, Albert ^b   Kastrati, Adnan ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b NONE

Author keywords

Coronary heart disease; Coronary stent; Genetics; Leucine 7; Mitogen; Neointima; Polymorphism; Preproneuropeptide Y; Proline 7; Restenosis; Vascular smooth muscle cells

Indexed keywords

LEUCINE; MITOGENIC AGENT; NEUROPEPTIDE Y; PROLINE; SIGNAL PEPTIDE;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; ELECTROCARDIOGRAM; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; OLIGONUCLEOTIDE PROBE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREPRONEUROPEPTIDE Y GENE; PRIORITY JOURNAL; RESTENOSIS; SUDDEN DEATH; VASCULAR SMOOTH MUSCLE;

CORONARY RESTENOSIS; HUMANS; LEUCINE; MIDDLE AGED; NEUROPEPTIDE Y; POLYMORPHISM, GENETIC; PROLINE; PROTEIN PRECURSORS; STENTS;

EID: 0141478976     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/1545-1550(2003)010<0566:LTPPOT>2.0.CO;2     Document Type: Article

References (31)

1. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998;83:187-195.
2. Karvonen MK, Pesonen U, Koulu M, et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med. 1998;4:1434-1437.
3. Niskanen L, Karvonen MK, Valve R, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab. 2000;85:2266-2269.
4. Karvonen MK, Valkonen VP, Lakka TA, et al. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis. 2001;159:145-151.
5. Kallio J, Pesonen U, Kaipio K, et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 2001;15:1242-1244.
6. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention: executive summary and recommendation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37:2215-2239.
7. Quarck R, Holvoet P. Restenosis and gene therapy. Expert Opin Biol Ther. 2001;1:79-91.
8. Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980.
9. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247-1254.
10. Kastrati A, Dirschinger J, Schomig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz. 2000;25:34-46.
11. Bonnici F, Keavney B, Collins R, et al. Angiotensin converting enzvme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies. BMJ. 2002;325:517-520.
12. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept. 1994;50:259-265.
13. Nilsson T, Edvinsson L. Neuropeptide Y stimulates DNA synthesis in human vascular smooth muscle cells through neuropeptide Y Y1 receptors. Can J Physiol Pharmacol. 2000;78:256-259.
14. Levite M, Cahalon L, Hershkoviz R, et al. Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. J Immunol. 1998;160:993-1000.
15. Koch W, Kastrati A, Mehilli J, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation. 2000;102:197-202.
16. Kastrati A, Schomig A, Elezi S, et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation. 1999;100:1285-1290.
17. Ellis SG, Vandormael M, Cowley M, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990;82:1193-1202.
18. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 1999;14:143-149.
19. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87-92.
20. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportion. Am Stat. 1998;52:119-126.
21. Franco-Cereceda A, Grip LG, Moor E, et al. Influence of percutaneous transluminal coronary angioplasty on cardiac release of endothelin, neuropeptide Y and noradrenaline. Int J Cardiol. 1995;48:231-233.
22. Milner P, Crowe R, Loesch A, et al. Neurocompensatory responses to balloon-catheter-induced injury of the rat carotid artery. J Vasc Res. 1997;34:31-40.
23. Persson H, Andreasson K, Kahan T, et al. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail. 2002;4:73-82.
24. Asakura M, Ueda Y, Nanto S, et al. Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up. Circulation. 1998;97:2003-2006.
25. Franco-Cereceda A, Owall A, Settergren G, et al. Release of neuropeptide Y and noradrenaline from the human heart after aortic occlusion during coronary artery surgery. Cardiovasc Res. 1990;24:242-246.
26. Ullman B, Franco-Cereceda A, Hulting J, et al. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med. 1990;228:583-589.
27. Gullestad L, Jorgensen B, Bjuro T, et al. Post-exercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease. Circulation. 2000;102:987-993.
28. Ullman B, Hulting J, Lundberg JM. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J. 1994;15:454-461.
29. Bauters C, Lamblin N, Amouyel P. Gene polymorphisms and outcome after coronary angioplasty. Curr Interv Cardiol Rep. 2001;3:281-286.
30. Bennett MR, O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther. 2001;91:149-166.
31. Zee RY, Hoh J, Cheng S, et al. Multi-locus interactions predict risk for post-PTCA restenosis: an approach to the genetic analysis of common complex disease. Pharmacogenomics J. 2002;2:197-201.